The Food and Drug Administration has kicked off a voluntary pilot program to help promote the safety of drugs, and active drug ingredients, produced outside the U.S. The FDA plans to select 100 applicants to participate in the Secure Supply Chain pilot program.
To qualify, applicants will need to meet the pilot program’s criteria, including a requirement that they maintain control over the drug products from the time of manufacture through entry into the country.
“With the increase of drug products produced outside the U.S., it is critical that the FDA concentrate its resources on companies that pose the highest risk,” said Michael Chappell, acting associate commissioner, FDA regulatory affairs.
The goal of the pilot is to allow FDA to determine the practicality program of developing a secure supply chain program. A secure supply chain will help mitigate risks such as contamination and counterfeiting.
“This initiative creates incentives for drug makers to develop and maintain secure supply chains,” said Deborah Autor, director of the Offi ce of Compliance in FDA’s Center for Drug Evaluation and Research. “This is one of several agency initiatives to enhance drug product safety.” The pilot program is scheduled to run for a period of two years.
